Abstract: Methods and apparatuses are provided for a virtual burrow assay for a diversity of neurological and psychiatric disorders. For example, a virtual burrow array device including a virtual, burrow, a linear actuator and one or more sensors is provided.

Abstract: Methods and apparatuses are provided for a virtual burrow assay for a diversity of neurological and psychiatric disorders. For example, a virtual burrow assay device including a virtual burrow (or enclosure), a linear actuator and one or more sensors is provided. A novel rail system is configured to have a lightweight configuration which, when coupled to the virtual burrow or enclosure, reduces inertia of the virtual burrow or enclosure and can facilitate nearly-frictionless motion of the virtual burrow or enclosure.

Abstract: Methods and apparatuses are provided for a virtual burrow assay for a diversity of neurological and psychiatric disorders. For example, a virtual burrow array device including a virtual, burrow, a linear actuator and one or more sensors is provided.

Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.

Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.

Abstract: This invention provides an isolated nucleic acid encoding an insect gustatory or odorant receptor. This invention provides a nucleic acid of at least 12 nucleotides capable of specifically hybridizing with a nucleic acid encoding an insect gustatory or odorant receptor. This invention also provides a purified, insect gustatory or odorant receptor. This invention provides an antibody capable of specifically binding to an insect gustatory or odorant receptor. This invention provides a method of identifying a compound capable of specifically binding to, activating, or inhibiting the activity of an insect gustatory or odorant receptor. This invention also provides methods of controlling insect populations.

Abstract: This invention provides an isolated nucleic acid encoding an insect gustatory or odorant receptor. This invention provides a nucleic acid of at least 12 nucleotides capable of specifically hybridizing with a nucleic acid encoding an insect gustatory or odorant receptor. This invention also provides a purified, insect gustatory or odorant receptor. This invention provides an antibody capable of specifically binding to an insect gustatory or odorant receptor. This invention provides a method of identifying a compound capable of specifically binding to, activating, or inhibiting the activity of an insect gustatory or odorant receptor. This invention also provides methods of controlling insect populations.

Abstract: This invention provides an isolated nucleic acid molecule encoding an insect odorant receptor. This invention provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with the nucleic acid molecule encoding an insect odorant receptor. This invention also provides a purified, insect odorant receptor. This invention provides an antibody capable of specifically binding to an insect odorant receptor. This invention provides a method for identifying cDNA inserts encoding an insect odorant receptors. This invention provides a method of identifying a compound capable of specifically bind to an insect odorant receptor. This invention also provides a method of identifying a compound capable of activating the activity of an insect odorant receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding an insect odorant receptor. This invention provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with the nucleic acid molecule encoding an insect odorant receptor. This invention also provides a purified, insect odorant receptor. This invention provides an antibody capable of specifically binding to an insect odorant receptor. This invention provides a method for identifying cDNA inserts encoding an insect odorant receptors. This invention provides a method of identifying a compound capable of specifically bind to an insect odorant receptor. This invention also provides a method of identifying a compound capable of activating the activity of an insect odorant receptor.

Abstract: This invention provides methods for producing a membrane-bound protein in mammalian cells. This invention also provides nucleic acids for making novel fusion proteins (e.g., GPCR fusion proteins). This invention further provides related bacterial expression vectors; expression methods; fusion proteins; bacterial cells; GPCR vector screens; bacterial spheroplasts; methods for making anti-GPCR antibodies; and GPCR binding screens. This invention also provides a method for identifying a reagent in which a membrane protein is likely to crystallize. Finally, this invention provides methods for producing crystals of a protein which, in a cell, is a membrane-bound protein.

Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.

Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.

Abstract: The invention relates to a method for determining if a test compound, or a mix of compounds, modulates the interaction between two proteins of interest. The determination is made possible via the use of two recombinant molecules, one of which contains the first protein a cleavage site for a proteolytic molecules, and an activator of a gene. The second recombinant molecule includes the second protein and the proteolytic molecule. If the test compound binds to the first protein, a reaction is initiated whereby the activator is cleaved, and activates a reporter gene.

Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185.

Abstract: This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide comprises the amino acid sequence shown in FIG. 6 from about +1 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus.

Abstract: This invention provides an isolated nucleic acid molecule encoding an insect odorant receptor. This invention provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with the nucleic acid molecule encoding an insect odorant receptor. This invention also provides a purified, insect odorant receptor. This invention provides an antibody capable of specifically binding to an insect odorant receptor. This invention provides a method for identifying cDNA inserts encoding an insect odorant receptors. This invention provides a method of identifying a compound capable of specifically bind to an insect odorant receptor. This invention also provides a method of identifying a compound capable of activating the activity of an insect odorant receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding an insect odorant receptor. This invention provides a nucleic acid molecule of at least 12 nucleotides capable of specifically hybridizing with the nucleic acid molecule encoding an insect odorant receptor. This invention also provides a purified, insect odorant receptor. This invention provides an antibody capable of specifically binding to an insect odorant receptor. This invention provides a method for identifying cDNA inserts encoding an insect odorant receptors. This invention provides a method of identifying a compound capable of specifically bind to an insect odorant receptor. This invention also provides a method of identifying a compound capable of activating the activity of an insect odorant receptor.

Abstract: A single-stranded nucleic acid molecule which encodes an amino acid sequence comprising at least a portion of a T4 glycoprotein is provided. Additionally, amino acid sequences which comprise at least a portion of a T4 glycoprotein and are useful as a prophylaxis for treating a subject with acquired immune deficiency syndrome are provided. These amino acid sequences, which are capable of specifically forming a complex with a human immunodeficiency virus envelope glycoprotein and which are soluble in an aqueous solution may be administered to a subject infected with a human immunodeficiency virus so as to block the human immunodeficiency virus from binding to T4+ cells. Monoclonal antibodies directed to the water-soluble amino acid sequences of the present invention may be used as vaccines for immunizing a subject against acquired immune deficiency syndrome.

Abstract: This invention provides an isolated nucleic acid encoding an insect gustatory or odorant receptor. This invention provides a nucleic acid of at least 12 nucleotides capable of specifically hybridizing with a nucleic acid encoding an insect gustatory or odorant receptor. This invention also provides a purified, insect gustatory or odorant receptor. This invention provides an antibody capable of specifically binding to an insect gustatory or odorant receptor. This invention provides a method of identifying a compound capable of specifically binding to, activating, or inhibiting the activity of an insect gustatory or odorant receptor. This invention also provides methods of controlling insect populations.

Abstract: The invention relates to processes for inserting into eucaryotic cells a multiplicity of DNA molecules which includes genes coding for desired proteinaceous materials. The insertion of multiple copies of desired genes is accomplished by cotransformation with the desired genes and with amplifiable genes for a dominant selectable marker in the presence of successively higher amounts of an inhibitor. Alternatively, the insertion of multiple copies of desired genes is accomplished by transformation using DNA molecules formed by ligating a DNA molecule including the desired gene to a DNA molecule which includes an amplifiable gene coding for a dominant selectable phenotype such as a gene associated with resistance to a drug in the presence of successively higher amounts of an agent such as a drug against which the gene confers resistance so that only those eucaryotic cells into which multiple copies of the amplifiable gene have been inserted survive.